Painchek (ASX:PCK) Momentum Rank: 6 (As of Aug. 12, 2026) — Near Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ASX:PCK Painchek Ltd ASX:PCK
49 GF Score
Price A$0.11
GF Value A$0.41
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is Painchek Momentum Rank?

Painchek ASX:PCK 49 Momentum Rank is 6 as of Aug. 12, 2026, which is at its 10-year median of 6.00. GuruFocus rates ASX:PCK with a GF Score™ of 49/100 and a GF Value™ of A$0.41 (Possible Value Trap). The stock has 3 warning signs investors should review.

Painchek has the Momentum Rank of 6.

Momentum Rank measures the strength and persistence of a stock's price movement over time, rated on a scale of 1 to 10.

For Momentum Rank, we considered the residual momentum concept that was widely studied by Blitz and his colleagues as well as by Nobel Prize laureates Fama and French. However, we did not find any significant differences in the performances of stocks with different ranks of residual momentum. Therefore, we use traditional momentum instead.

Momentum Rank is determined using the standardized momentum ratio and other momentum indicators. The standardized momentum ratio is the average of the performances from 12 months ago to 1 month ago and 6 months ago to 1 month ago, divided by the beta of the stock over the past 12 months. To calculate the momentum ratio today, we would use the average of the two performance numbers.

For momentum, we found that stock price performance does not have a monotonic correlation with the momentum ratio. The stocks with the highest momentum ratios perform worse than those at about the 70th percentile. Therefore, for the momentum rank, we ranked the stocks at about the 70th percentile of the momentum ratio as the highest at 10.

A higher score reflects strong price momentum and indicates greater potential for superior performance. Conversely, a lower score indicates that momentum is either too high or too low, and stocks tend to underperform.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.

ASX:PCK vs VEEV, BTSG, HQY: Momentum Rank Comparison

For the Health Information Services subindustry, Painchek's Momentum Rank, along with its competitors' market caps and Momentum Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Painchek Momentum Rank vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Painchek's Momentum Rank distribution charts can be found below:

* The bar in red indicates where Painchek's Momentum Rank falls into.


ASX:PCK
49GF Score
Painchek Ltd ASX:PCK
Momentum Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Momentum Rank →
What does a Momentum Rank of 6 mean?
Painchek (ASX:PCK) has a Momentum Rank of 6 as of Aug. 12, 2026. Momentum Rank is determined using the standardized momentum ratio, measuring the speed and velocity of price changes in a stock. View historical data on Painchek and its competitors. This is near median its historical median of 6.00. Over the past decade, Painchek's Momentum Rank has ranged from 1.00 to 10.00.
Is Painchek's Momentum Rank too high?
Painchek's current Momentum Rank of 6 is near median its 10-year median of 6.00. Over the past 10 years, this metric has ranged from a low of 1.00 to a high of 10.00. Overall, Painchek has a GF Score™ of 49/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Painchek's Momentum Rank compare to VEEV and BTSG?
Painchek's Momentum Rank of 6 can be compared against companies in the Healthcare Providers & Services industry. Historically, Painchek's own Momentum Rank has ranged from 1.00 to 10.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Momentum Rank for a Healthcare Providers & Services company?
A good Momentum Rank depends on the Healthcare Providers & Services industry context. However, Momentum Rank should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Momentum Rank mean?
A high Momentum Rank can signal that a stock is expensive relative to its fundamentals. Momentum Rank is determined using the standardized momentum ratio, measuring the speed and velocity of price changes in a stock. View historical data on Painchek and its competitors. Painchek's current Momentum Rank is 6, which is near median its own 10-year median of 6.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Painchek stock overvalued right now?
Based on GuruFocus' analysis, Painchek (ASX:PCK) is currently considered Possible Value Trap. The stock's GF Value™ is A$0.41, compared to a current price of A$0.11 — trading 74.4% below its estimated fair value. The current Momentum Rank is 6, which is near median its 10-year median of 6.00. Painchek's overall GF Score™ is 49/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Momentum Rank calculated?
Momentum Rank is calculated from a company's financial statements. For Painchek (ASX:PCK), the current Momentum Rank is 6 as of Aug. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Painchek (ASX:PCK) Overvalued in 2026?

Based on GuruFocus' analysis, Painchek stock appears to be undervalued. The current stock price of A$0.11 is trading 74.4% below its estimated GF Value™ of A$0.41. GuruFocus considers Painchek to be Possible Value Trap.

Key valuation signals for ASX:PCK:

  • Momentum Rank: 6 (near median its 10-year median of 6.00)
  • GF Value™: A$0.41 vs. price of A$0.11 (74.4% below fair value)
  • GF Score™: 49/100 with 3 warning signs

No single metric tells the full story. See the ASX:PCK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Painchek Business Description

Address 35 Lime Street, Suite 401, Sydney, NSW, AUS, 2000
Painchek Ltd is engaged in the development and commercialization of mobile medical device applications that provide pain assessment for individuals who are unable to communicate pain with carers. It operates in one segment, namely the sale of its pain assessment solutions. Its geographic segments include Australia, the United Kingdom, and Other countries, of which it generates the majority of its revenue from Australia.
49GF Score

Get the complete analysis for ASX:PCK

Momentum Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.11
Price
A$0.41
GF Value